Pipex Pharmaceuticals Receives FDA Orphan Drug Designation For Oral TTM For Idiopathic Pulmonary Fibrosis (IPF)
May 15th 2008Drug InformationRespiratory
Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and autoimmune diseases, announced that it has received an Orphan Drug designation for oral tetrathiomolybdate (oral TTM) from the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a deadly pulmonary disease with no FDA-approved therapy.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
